AU692155B2 - Method and composition for treatment of osteoporosis - Google Patents

Method and composition for treatment of osteoporosis Download PDF

Info

Publication number: AU692155B2
Authority: AU; Australia
Prior art keywords: estrogen; potassium salt; administered; human; combination
Prior art date: 1993-04-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU66219/94A

Other languages

English (en)

Other versions

AU6621994A (en

Inventor

R. Curtis Morris Jr.

Anthony Sebastian

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of California

Original Assignee

University of California Berkeley

University of California San Diego UCSD

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-04-02

Filing date

1994-03-29

Publication date

1998-06-04

1994-03-29 Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley

1994-10-24 Publication of AU6621994A publication Critical patent/AU6621994A/en

1998-06-04 Application granted granted Critical

1998-06-04 Publication of AU692155B2 publication Critical patent/AU692155B2/en

2014-03-29 Anticipated expiration legal-status Critical

Status Ceased legal-status Critical Current

Links

208000001132 Osteoporosis Diseases 0.000 title claims description 42
238000000034 method Methods 0.000 title claims description 25
238000011282 treatment Methods 0.000 title claims description 23
239000000203 mixture Substances 0.000 title description 16
239000000262 estrogen Substances 0.000 claims description 90
229940011871 estrogen Drugs 0.000 claims description 90
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 37
230000029142 excretion Effects 0.000 claims description 18
239000002552 dosage form Substances 0.000 claims description 15
230000002485 urinary effect Effects 0.000 claims description 15
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 13
229910052791 calcium Inorganic materials 0.000 claims description 13
239000011575 calcium Substances 0.000 claims description 13
229940000425 combination drug Drugs 0.000 claims description 13
229940035811 conjugated estrogen Drugs 0.000 claims description 13
229940079593 drug Drugs 0.000 claims description 12
239000003814 drug Substances 0.000 claims description 12
229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 11
150000003839 salts Chemical class 0.000 claims description 11
239000004480 active ingredient Substances 0.000 claims description 10
239000011736 potassium bicarbonate Substances 0.000 claims description 10
235000015497 potassium bicarbonate Nutrition 0.000 claims description 10
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical group [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 10
102000008186 Collagen Human genes 0.000 claims description 9
108010035532 Collagen Proteins 0.000 claims description 9
229920001436 collagen Polymers 0.000 claims description 9
229910052739 hydrogen Inorganic materials 0.000 claims description 9
239000011574 phosphorus Substances 0.000 claims description 9
229910052698 phosphorus Inorganic materials 0.000 claims description 9
159000000001 potassium salts Chemical class 0.000 claims description 9
210000002700 urine Anatomy 0.000 claims description 9
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 8
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 8
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 8
229960002591 hydroxyproline Drugs 0.000 claims description 8
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 8
230000001009 osteoporotic effect Effects 0.000 claims description 7
201000010099 disease Diseases 0.000 claims description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
150000001735 carboxylic acids Chemical class 0.000 claims description 4
239000012530 fluid Substances 0.000 claims description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
150000002148 esters Chemical class 0.000 claims description 3
239000001257 hydrogen Substances 0.000 claims description 3
238000001727 in vivo Methods 0.000 claims description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
229910052760 oxygen Inorganic materials 0.000 claims description 3
239000001301 oxygen Substances 0.000 claims description 3
239000003795 chemical substances by application Substances 0.000 claims description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 2
150000001875 compounds Chemical class 0.000 claims 2
239000003937 drug carrier Substances 0.000 claims 2
239000011591 potassium Substances 0.000 claims 2
229910052700 potassium Inorganic materials 0.000 claims 2
OWYWGLHRNBIFJP-UHFFFAOYSA-N Ipazine Chemical compound CCN(CC)C1=NC(Cl)=NC(NC(C)C)=N1 OWYWGLHRNBIFJP-UHFFFAOYSA-N 0.000 claims 1
241001648341 Orites Species 0.000 claims 1
101100499939 Schizosaccharomyces pombe (strain 972 / ATCC 24843) cdm1 gene Proteins 0.000 claims 1
230000000694 effects Effects 0.000 description 14
239000004615 ingredient Substances 0.000 description 14
239000000583 progesterone congener Substances 0.000 description 8
239000003826 tablet Substances 0.000 description 8
230000011164 ossification Effects 0.000 description 7
230000036541 health Effects 0.000 description 6
102000004067 Osteocalcin Human genes 0.000 description 5
108090000573 Osteocalcin Proteins 0.000 description 5
239000006187 pill Substances 0.000 description 5
206010014733 Endometrial cancer Diseases 0.000 description 4
206010014759 Endometrial neoplasm Diseases 0.000 description 4
241000282412 Homo Species 0.000 description 4
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
235000018823 dietary intake Nutrition 0.000 description 4
-1 phosphorus ion Chemical class 0.000 description 4
239000007787 solid Substances 0.000 description 4
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 3
208000006386 Bone Resorption Diseases 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
210000000988 bone and bone Anatomy 0.000 description 3
230000024279 bone resorption Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
230000007423 decrease Effects 0.000 description 3
210000003608 fece Anatomy 0.000 description 3
239000008187 granular material Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000003550 marker Substances 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
230000036515 potency Effects 0.000 description 3
239000000843 powder Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
VOXZDWNPVJITMN-SFFUCWETSA-N 17α-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-SFFUCWETSA-N 0.000 description 2
ZAHDXEIQWWLQQL-IHRRRGAJSA-N Deoxypyridinoline Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(O)=C(C[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 ZAHDXEIQWWLQQL-IHRRRGAJSA-N 0.000 description 2
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 2
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
LCYXYLLJXMAEMT-SAXRGWBVSA-N Pyridinoline Chemical compound OC(=O)[C@@H](N)CCC1=C[N+](C[C@H](O)CC[C@H](N)C([O-])=O)=CC(O)=C1C[C@H](N)C(O)=O LCYXYLLJXMAEMT-SAXRGWBVSA-N 0.000 description 2
230000008901 benefit Effects 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
230000000740 bleeding effect Effects 0.000 description 2
239000013078 crystal Substances 0.000 description 2
150000002009 diols Chemical class 0.000 description 2
229960005309 estradiol Drugs 0.000 description 2
238000009164 estrogen replacement therapy Methods 0.000 description 2
VUCAHVBMSFIGAI-ZFINNJDLSA-M estrone sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 VUCAHVBMSFIGAI-ZFINNJDLSA-M 0.000 description 2
229960002568 ethinylestradiol Drugs 0.000 description 2
238000009472 formulation Methods 0.000 description 2
238000002955 isolation Methods 0.000 description 2
230000007774 longterm Effects 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
ODYKCPYPRCJXLY-PZORDLPLSA-N quinestradol Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1C[C@@H](O)[C@@H]4O)C)CC2=CC=3OC1CCCC1 ODYKCPYPRCJXLY-PZORDLPLSA-N 0.000 description 2
230000009467 reduction Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000007910 systemic administration Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
NLLMJANWPUQQTA-UHFFFAOYSA-N 13-methyl-6,9,11,12,14,15,16,17-octahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2C3CCC(C)(C(CC4)O)C4C3=CCC2=C1 NLLMJANWPUQQTA-UHFFFAOYSA-N 0.000 description 1
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
101100231509 Caenorhabditis elegans ceh-6 gene Proteins 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
WKRLQDKEXYKHJB-UHFFFAOYSA-N Equilin Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3=CCC2=C1 WKRLQDKEXYKHJB-UHFFFAOYSA-N 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
208000030136 Marchiafava-Bignami Disease Diseases 0.000 description 1
208000029725 Metabolic bone disease Diseases 0.000 description 1
206010030247 Oestrogen deficiency Diseases 0.000 description 1
HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
241000287433 Turdus Species 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
239000003150 biochemical marker Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
230000004097 bone metabolism Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
239000012059 conventional drug carrier Substances 0.000 description 1
239000013256 coordination polymer Substances 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
BOTLEXFFFSMRLQ-UHFFFAOYSA-N cyclopentyloxycyclopentane Chemical compound C1CCCC1OC1CCCC1 BOTLEXFFFSMRLQ-UHFFFAOYSA-N 0.000 description 1
PDRGHUMCVRDZLQ-UHFFFAOYSA-N d-equilenin Natural products OC1=CC=C2C(CCC3(C4CCC3=O)C)=C4C=CC2=C1 PDRGHUMCVRDZLQ-UHFFFAOYSA-N 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
235000015872 dietary supplement Nutrition 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
208000016018 endometrial polyp Diseases 0.000 description 1
PDRGHUMCVRDZLQ-WMZOPIPTSA-N equilenin Chemical compound OC1=CC=C2C(CC[C@]3([C@H]4CCC3=O)C)=C4C=CC2=C1 PDRGHUMCVRDZLQ-WMZOPIPTSA-N 0.000 description 1
WKRLQDKEXYKHJB-HFTRVMKXSA-N equilin Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 WKRLQDKEXYKHJB-HFTRVMKXSA-N 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
229950002007 estradiol benzoate Drugs 0.000 description 1
230000001076 estrogenic effect Effects 0.000 description 1
229960003399 estrone Drugs 0.000 description 1
230000012173 estrus Effects 0.000 description 1
208000020694 gallbladder disease Diseases 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000002175 menstrual effect Effects 0.000 description 1
IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 description 1
229960001390 mestranol Drugs 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
230000001452 natriuretic effect Effects 0.000 description 1
210000000963 osteoblast Anatomy 0.000 description 1
229940094984 other estrogen in atc Drugs 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
239000001508 potassium citrate Substances 0.000 description 1
229960002635 potassium citrate Drugs 0.000 description 1
QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
235000011082 potassium citrates Nutrition 0.000 description 1
239000004224 potassium gluconate Substances 0.000 description 1
229960003189 potassium gluconate Drugs 0.000 description 1
235000013926 potassium gluconate Nutrition 0.000 description 1
229940063238 premarin Drugs 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
229960004726 quinestradol Drugs 0.000 description 1
229960001424 quinestrol Drugs 0.000 description 1
PWZUUYSISTUNDW-VAFBSOEGSA-N quinestrol Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@]4(O)C#C)C)CC2=CC=3OC1CCCC1 PWZUUYSISTUNDW-VAFBSOEGSA-N 0.000 description 1
239000008299 semisolid dosage form Substances 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
229960004249 sodium acetate Drugs 0.000 description 1
229960000747 sodium estrone sulfate Drugs 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
239000013589 supplement Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000009424 thromboembolic effect Effects 0.000 description 1
230000001732 thrombotic effect Effects 0.000 description 1
229940117013 triethanolamine oleate Drugs 0.000 description 1
229960004418 trolamine Drugs 0.000 description 1
206010046811 uterine polyp Diseases 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Physical Education & Sports Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Inorganic Chemistry (AREA)
Hematology (AREA)
Diabetes (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AU66219/94A 1993-04-02 1994-03-29 Method and composition for treatment of osteoporosis Ceased AU692155B2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US4234993A	1993-04-02	1993-04-02
US042349		1993-04-02
PCT/US1994/003402 WO1994022457A1 (en)	1993-04-02	1994-03-29	Method and composition for treatment of osteoporosis

Publications (2)

Publication Number	Publication Date
AU6621994A AU6621994A (en)	1994-10-24
AU692155B2 true AU692155B2 (en)	1998-06-04

Family

ID=21921399

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU66219/94A Ceased AU692155B2 (en)	1993-04-02	1994-03-29	Method and composition for treatment of osteoporosis

Country Status (8)

Country	Link
EP (1)	EP0692965A4 (de)
JP (1)	JPH08508502A (de)
KR (1)	KR960701642A (de)
CN (1)	CN1120314A (de)
AU (1)	AU692155B2 (de)
BR (1)	BR9406101A (de)
CA (1)	CA2159354A1 (de)
WO (1)	WO1994022457A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR0208165A (pt) *	2001-03-16	2004-03-30	Wyeth Corp	Composições farmacêuticas e seus usos na terapia de reposição de estrogênio
AU2004264899A1 (en) *	2003-08-06	2005-02-24	Innophos, Inc.	Method for promoting bone growth
US10221116B2 (en) *	2014-04-02	2019-03-05	Shell Oil Company	Process for the separation of monoethylene glycol and 1,2-butanediol

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3608077A (en) *	1969-11-13	1971-09-21	Syntex Corp	Stabilization of metal steroid alcohol sulfates
US4078060A (en) *	1976-05-10	1978-03-07	Richardson-Merrell Inc.	Method of inducing an estrogenic response
US4261985A (en) *	1978-11-22	1981-04-14	Ciba-Geigy Corporation	Novel diuretics
US4617298A (en) *	1985-10-22	1986-10-14	University Of Florida	Method and compositions for weight control
US4814177A (en) *	1986-03-18	1989-03-21	Board Of Regents, University Of Texas System	Ultradense and more soluble and bioavailable preparations of calcium citrate
US5171583A (en) *	1988-10-21	1992-12-15	The Regents Of The University Of California	Treatment of osteoporosis using potassium bicarbonate

1994
- 1994-03-29 CN CN94191682A patent/CN1120314A/zh active Pending
- 1994-03-29 AU AU66219/94A patent/AU692155B2/en not_active Ceased
- 1994-03-29 WO PCT/US1994/003402 patent/WO1994022457A1/en not_active Ceased
- 1994-03-29 KR KR1019950704281A patent/KR960701642A/ko not_active Withdrawn
- 1994-03-29 EP EP94913970A patent/EP0692965A4/de not_active Withdrawn
- 1994-03-29 BR BR9406101A patent/BR9406101A/pt not_active Application Discontinuation
- 1994-03-29 JP JP6522294A patent/JPH08508502A/ja active Pending
- 1994-03-29 CA CA002159354A patent/CA2159354A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP0692965A1 (de)	1996-01-24
CN1120314A (zh)	1996-04-10
WO1994022457A1 (en)	1994-10-13
AU6621994A (en)	1994-10-24
CA2159354A1 (en)	1994-10-13
EP0692965A4 (de)	1998-08-12
BR9406101A (pt)	1995-12-19
JPH08508502A (ja)	1996-09-10
KR960701642A (ko)	1996-03-28

Publication	Publication Date	Title
EP0686037B1 (de)	2001-06-20	Hormon-ersatztherapie
US6139873A (en)	2000-10-31	Combined pharmaceutical estrogen-androgen-progestin
US5962021A (en)	1999-10-05	Combined pharmaceutical estrogen-androgen-progestin oral contraceptive
Agnusdei et al.	1995	Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug ipriflavone
WO2018024912A1 (en)	2018-02-08	Method for the management of dysmenorrhea and menstrual pain
CA2208007A1 (en)	1996-06-27	Cyclophasic hormonal regimen containing antiprogestin and progestin
KR100782638B1 (ko)	2007-12-06	에스트로겐 화합물 및 프로게스테론 화합물로 이루어진호르몬 조성물
JP2942560B2 (ja)	1999-08-30	エストロゲン欠乏症治療用組成物
AU692155B2 (en)	1998-06-04	Method and composition for treatment of osteoporosis
EP0190851B1 (de)	1990-01-03	Entzündungshemmende Zusammensetzung
US5932252A (en)	1999-08-03	Method and composition for treatment of osteoporosis
JPWO1994026768A1 (ja)	1995-08-03	骨形成促進剤ならびに骨粗鬆症治療剤
CA2309745A1 (en)	1999-05-27	Progestogen-antiprogestogen regimens
EP0691814B1 (de)	2002-06-26	Verfahren und zusammensetzungen zur behandlung der osteoporose
Fitzpatrick	2003	Clinical trials of estrogen and SERMs on bone markers, bone mineral density, and fractures
AU640112B2 (en)	1993-08-19	Estrogen and progestogen containing oral dosage forms
MXPA99001793A (en)	2000-02-02	Transdermal therapeutical approach involving a combination of active substances containing oestriol
Fitzpatrick	2005	Pharmaceuticals for Bone Disease Targeting the Osteoclast
SK25299A3 (en)	2000-08-14	Transdermal therapeutical approach involving a combination of active substances containing oestriol